FDC

Which are the latest news on FDC?

Why is FDC Ltd falling/rising?

As of 04-Aug, FDC Ltd's stock price is at 403.00, showing a slight decline and negative performance over various periods. Despite being net-debt free and reporting significant profit growth, the stock is underperforming compared to the benchmark Sensex and trading below its moving averages.

As of 04-Aug, FDC Ltd's stock price is currently at 403.00, reflecting a slight decline of 0.05 (-0.01%). The stock has shown a negative performance over various periods, including a 1-week drop of 1.16% and a 1-month decrease of 6.98%. Year-to-date, the stock is down 4.80%, and over the past year, it has fallen by 16.33%. <BR><BR>Despite these declines, there are some positive indicators. The company is net-debt free and recently reported positive results for the quarter ending March 2026, marking a turnaround after two consecutive negative quarters. The profit after tax (PAT) for the latest six months has grown significantly by 95.31%, and the profit before tax (PBT) has also increased by 68.0% compared to the previous four-quarter average. <BR><BR>Additionally, there has been a notable increase in investor participation, with delivery volume rising by 266.52% against the 5-day average, indicating growing interest in the stock. However, the stock's performance today is described as inline with the sector, and it is currently trading lower than its 5-day, 20-day, and 50-day moving averages, which may contribute to the perception of a downward trend. <BR><BR>Overall, while there are some positive developments, the recent price decline and underperformance relative to the benchmark Sensex, which has risen by 2.17% over the past week, suggest that FDC Ltd is currently experiencing a falling stock price.

When is the next results date for FDC Ltd?

The next results date for FDC Ltd is 05 August 2026.

The next results date for FDC Ltd is scheduled for 05 August 2026.

Should I buy, sell or hold FDC Ltd?

How big is FDC?

As of 10th June, FDC Ltd has a market capitalization of 6,389.00 Cr, with recent Net Sales of 2,170.94 Cr and a Net Profit of 281.42 Cr. Shareholder's Funds are 2,281.08 Cr and Total Assets amount to 2,713.80 Cr.

As of 10th June, FDC Ltd has a market capitalization of 6,389.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, FDC reported Net Sales of 2,170.94 Cr and a Net Profit of 281.42 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 2,281.08 Cr and Total Assets of 2,713.80 Cr.

Who are in the management team of FDC?

The management team of FDC includes key members such as Mohan A Chandavarkar (Managing Director), Ameya A Chandavarkar (Executive Director & CEO), and Uday Kumar Gurkar (Chairman & Independent Director), among others, who oversee the company's strategic direction and operations.

The management team of FDC includes the following key members:<BR><BR>1. **Mohan A Chandavarkar** - Managing Director<BR>2. **Ashok A Chandavarkar** - Director<BR>3. **Nandan M Chandavarkar** - Joint Managing Director<BR>4. **Ameya A Chandavarkar** - Executive Director & CEO<BR>5. **Ramdas A Chandavarkar** - Chairman Emeritus<BR>6. **Varsharani Katre** - Company Secretary & Compliance Officer<BR>7. **Nomita R Chandavarkar** - Director<BR>8. **Swati S Mayekar** - Independent Director<BR>9. **Uday Kumar Gurkar** - Chairman & Independent Director<BR>10. **Melarkode Ganesan Parameswaran** - Independent Director<BR>11. **Usha Athreya Chandrasekhar** - Independent Director<BR>12. **Mahesh Bijlani** - Independent Director<BR>13. **Vijay Maniar** - Additional Independent Director<BR><BR>This team is responsible for guiding the strategic direction and operations of the company.

Who are the peers of the FDC?

FDC's peers include Blue Jet Health, Supriya Lifesci., Sanofi India, SPARC, Aarti Pharma, Senores Pharma, Innova Captab, Bliss GVS Pharma, and Guj. Themis Bio. Key insights show varying management risks, growth rates, and capital structures, with Senores Pharma achieving the highest 1-year return at 118.08% and Sanofi India the lowest at -48.78%.

Peers: The peers of FDC are Blue Jet Health, Supriya Lifesci., Sanofi India, SPARC, Aarti Pharma, Senores Pharma., Innova Captab, Bliss GVS Pharma, and Guj. Themis Bio.<BR><BR>Quality Snapshot: Excellent management risk is observed at Blue Jet Health, Supriya Lifesci., and Innova Captab, while Average management risk is found at SPARC, FDC, Aarti Pharma, and Bliss GVS Pharma, and the rest. Good management risk is noted at Guj. Themis Bio. In terms of growth, Excellent growth is seen at SPARC and Senores Pharma., while Below Average growth is present at Blue Jet Health, Supriya Lifesci., Sanofi India, FDC, Aarti Pharma, Innova Captab, Bliss GVS Pharma, and the rest. Excellent capital structure is attributed to Blue Jet Health, Supriya Lifesci., Sanofi India, Aarti Pharma, Innova Captab, Bliss GVS Pharma, Guj. Themis Bio., while Average capital structure is found at SPARC, and Good capital structure is noted at Senores Pharma.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Senores Pharma. at 118.08%, while the lowest is Sanofi India at -48.78%. FDC's own 1-year return is -15.33%, which is higher than Sanofi India's but lower than Senores Pharma's. Additionally, Aarti Pharma and Guj. Themis Bio. have negative six-month returns.

What does FDC do?

FDC Ltd is a research-oriented pharmaceutical company in India, specializing in manufacturing and marketing formulations and active pharmaceutical ingredients. As of March 2026, it reported net sales of ₹585 Cr and a net profit of ₹103 Cr, with a market cap of ₹6,389 Cr.

Overview:<BR>FDC Ltd is a fully integrated, research-oriented pharmaceutical company engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients, operating within the Pharmaceuticals & Biotechnology industry and classified as a Small Cap company.<BR><BR>History:<BR>FDC Ltd was incorporated in an unspecified year and has maintained its status as a prominent player in the Indian pharmaceutical industry. The latest quarterly results reported are for March 2026, showing net sales and profit figures.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 585 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 103 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 6,389 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 21.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 1.27% <BR>Debt Equity: -0.20 <BR>Return on Equity: 11.98% <BR>Price to Book: 2.58 <BR><BR>Contact Details:<BR>Address: B-8 MIDC Industrial Area, Waluj Dist Aurangabad (Maharashtra) Maharashtra : 431136 <BR>Phone: 91-240-2554407/967/299 <BR>Email: investors@fdcindia.com <BR>Website: http://www.fdcindia.com

Are FDC Ltd latest results good or bad?

FDC Ltd's latest Q4 FY26 results show a significant net profit increase of 167.39% and revenue growth of 18.89%, but concerns arise from high reliance on other income and inconsistent operating margins, leading to a cautious outlook despite short-term market positivity.

FDC Ltd's latest results for Q4 FY26 show a mixed picture. On the positive side, the company reported a net profit of ₹103.40 crore, which is a remarkable increase of 167.39% year-on-year. Revenue also grew by 18.89% year-on-year to ₹584.79 crore, and the operating margin improved significantly to 18.19%, up from 10.97% in the same quarter last year.<BR><BR>However, there are notable concerns. A significant portion of the profit, about 35.55%, came from other income, which raises questions about the sustainability of the core business profitability. The company has experienced extreme quarterly volatility in its financial performance, with operating margins swinging widely across the year. This inconsistency suggests challenges in cost management and operational efficiency.<BR><BR>While the market has reacted positively in the short term, with the stock rallying recently, the overall performance over the past year has been disappointing, with the stock down nearly 7%. Given these factors, while the latest quarterly results show improvements, the underlying operational challenges and reliance on non-operating income indicate that the overall outlook remains cautious.

Is FDC technically bullish or bearish?

As of November 18, 2025, FDC's technical trend has shifted to a moderate bearish stance, driven by bearish MACD, moving averages, and Bollinger Bands, despite a conflicting bullish signal from the OBV on the monthly timeframe.

As of 18 November 2025, the technical trend has changed from mildly bearish to bearish. The current technical stance for FDC is bearish with a moderate strength. Key indicators driving this stance include a bearish MACD on the weekly timeframe, bearish moving averages on the daily timeframe, and a bearish signal from Bollinger Bands on both weekly and monthly timeframes. The KST is also bearish on the weekly, reinforcing the negative outlook. Although the OBV shows a bullish signal on the monthly, it does not outweigh the overall bearish indicators.

How has been the historical performance of FDC?

FDC has shown consistent growth in net sales, increasing from 1,090.70 Cr in Mar'19 to 2,108.12 Cr in Mar'25, while total assets rose to 2,713.80 Cr. However, profit margins and earnings per share have experienced volatility, with EPS declining from 18.75 in Mar'24 to 16.39 in Mar'25.

Answer:<BR>The historical performance of FDC shows a consistent growth trend in net sales and overall financial metrics over the years.<BR><BR>Breakdown:<BR>FDC's net sales have increased from 1,090.70 Cr in Mar'19 to 2,108.12 Cr in Mar'25, reflecting a steady growth trajectory. The total operating income has similarly risen, reaching 2,108.12 Cr in Mar'25 from 1,090.70 Cr in Mar'19. However, the total expenditure has also grown, amounting to 1,783.32 Cr in Mar'25, up from 859.68 Cr in Mar'19. Operating profit (PBDIT) has fluctuated, peaking at 440.17 Cr in Mar'24 before dropping to 415.46 Cr in Mar'25. Profit before tax reached 357.22 Cr in Mar'25, while profit after tax was recorded at 266.79 Cr. The earnings per share (EPS) decreased from 18.75 in Mar'24 to 16.39 in Mar'25, indicating a decline despite the growth in sales. On the balance sheet, total assets increased from 1,812.93 Cr in Mar'20 to 2,713.80 Cr in Mar'25, with total liabilities also rising to 2,713.80 Cr in Mar'25. Cash flow from operating activities improved significantly to 317.00 Cr in Mar'25 from 220.00 Cr in Mar'24, contributing to a net cash inflow of 26.00 Cr in Mar'25. Overall, FDC has demonstrated growth in sales and assets, although profit margins and EPS have shown some volatility.

Who are the top shareholders of the FDC?

The top shareholders of FDC include promoter Nomita R Chandavarkar with 22.67%, mutual funds at 6.18%, foreign institutional investors at 2.55%, and individual investors collectively owning 16.22%. The largest public shareholder is the ICICI Prudential Smallcap Fund, holding 2.87%.

The top shareholders of FDC include the promoters, who hold the majority of the shares. The promoter with the highest holding is Nomita R Chandavarkar, owning 22.67% of the company. In addition, mutual funds hold 6.18% of the shares through 10 different schemes, while foreign institutional investors (FIIs) hold 2.55% through 105 different entities. The highest public shareholder is the ICICI Prudential Smallcap Fund, which holds 2.87%. Individual investors collectively own 16.22% of the company.

Is FDC overvalued or undervalued?

As of March 5, 2025, FDC is considered overvalued with a valuation grade of expensive, reflected by a PE ratio of 26.12 and a year-to-date return of -12.40%, compared to the Sensex's 5.59%.

As of 5 March 2025, the valuation grade for FDC has moved from fair to expensive, indicating that the company is currently overvalued. The key ratios supporting this assessment include a PE ratio of 26.12, an EV to EBITDA of 20.33, and a Price to Book Value of 3.05. Compared to its peers, FDC's valuation appears high; for instance, Sun Pharma has a PE ratio of 35.25, while Cipla, considered attractive, has a PE of 22.99.<BR><BR>In light of these metrics, FDC is deemed overvalued relative to its industry peers. The company's recent stock performance has lagged behind the Sensex, with a year-to-date return of -12.40% compared to the Sensex's 5.59%, further reinforcing the notion that the stock may not be a favorable investment at its current price of 434.75.

Has FDC declared dividend?

FDC Ltd has declared a 500% dividend, amounting to ₹5 per share, with an ex-date of November 22, 2024. While recent returns have shown volatility, the company has demonstrated positive growth over the longer term, particularly in the 2 to 5-year periods.

FDC Ltd has declared a 500% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 500%<BR>- Amount per share: 5 per share<BR>- Ex-date: 22 Nov 24<BR><BR>Dividend Yield: 1.15%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -16.29%, with a dividend return of 0%, resulting in a total return of -16.29%.<BR><BR>Over the past year, the price return was -1.42%, the dividend return was 1.11%, leading to a total return of -0.31%.<BR><BR>In the 2-year period, the price return was 45.65%, the dividend return was 1.62%, culminating in a total return of 47.27%.<BR><BR>For the 3-year period, the price return was 75.79%, the dividend return was 2.16%, resulting in a total return of 77.95%.<BR><BR>In the last 4 years, the price return was 27.43%, the dividend return was 1.40%, leading to a total return of 28.83%.<BR><BR>Over the past 5 years, the price return was 64.51%, the dividend return was 1.86%, culminating in a total return of 66.37%.<BR><BR>Overall, FDC Ltd has declared a significant dividend, and while recent returns show some volatility, the longer-term performance indicates positive growth, particularly over the 2 to 5-year periods.